The main research aim of the Network for Optimized Astatine labeled Radiopharmaceuticals (NOAR) COST Action is to successfully demonstrate that one of the most promising radionuclides for Targeted Alpha Therapy (TAT), namely Astatine-211, can become the European standard for treatment of certain cancerous pathologies.
Contact Person at IST: António Paulo – apaulo@ctn.tecnico.ulisboa.pt